Title for MeetingAbstracts
Alphabetical listing of titles
GENOTYPIC PREDICTORS OF RESPONSE TO LOPINAVIR/RITONAVIR (LPV/r) IN CLINICAL PRACTICE.
Genotypic predictors of virologic response to stavudine after zidovudine monotherapy (ACTG 302).
Genotypic prevalence of transmitted ZDV- and ddI-resistant HIV-1 variants and natural polymorphism in protease coding region of seroconverters.
Genotypic prevalence of ZDV-resistant HIV-1 strains and preexistent mutations in protease coding region of recently infected subjects.
Genotypic resistance after CD4 guided structured treatment interruption in HIV infected patients pre-treated with dual NRTI before HAART.
Genotypic resistance after exposure to short-course AZT plus 3TC to prevent mother-to-child transmission in the women and her infected infants.
Genotypic resistance analysis following single-dose administration of nevirapine to HIV-infected women and their infants receiving short-course zidovudine.
Genotypic resistance analysis in french women participating in PACTG316/ANRS 083.
Genotypic resistance analysis in women participating in PACTG 316 with HIV-1 RNA > or = 10,000 copies/ml.
Genotypic resistance analysis in women participating in PACTG 316 with HIV-1 RNA >400 copies/ml.
Genotypic Resistance Analysis in Women Who Received Intrapartum Nevirapine Associated to a Short Course of Zidovudine to Prevent Perinatal HIV-1 Transmission: The Ditrame Plus ANRS 1201/02 Study, Abidjan, Cote d'Ivoire.
Genotypic Resistance as a tool to determine Salvage Regimen in Mexican individuals Failing to a Triple Therapy with Zidovudine (AZT), Lamivudine (3TC) and Indinavir (IDV).
Genotypic resistance assay for entire gp-41 sequence with identification of gp-41 polymorphisms in enfuvirtide-naive patients and new gp-41 mutations in patients failing enfuvirtide.
Genotypic resistance assay in multi-drug experienced HIV-1 infected patients: role in the choice of a salvage regimen.
Genotypic resistance at baseline fails to predict outcome among chronically infected, antiretroviral- therapy-naive patients in two large trials of pi-based regimens.
Genotypic resistance in antiretroviral-Naive HIV patients in Houston.
Genotypic Resistance in Patients with Primary HIV-1 Infection before and during HAART.
Genotypic resistance in treatment-naive patients.
Genotypic Resistance Mutation to Antiretroviral Drugs in Treatment-Naive HIV/AIDS Patients in the Northeast of China.
Genotypic Resistance of HIV-1 Isolates to Protease Inhibitors, Nonnucleoside Reverse Transcriptase Inhibitors, and Nucleoside Reverse Transcriptase Inhibitors from Antiretroviral Experienced and Naive Pregnant Women, 1995-2001.
Genotypic resistance patterns in HIV-infected naive patients receiving a four-drug combination therapy.
Genotypic resistance profiles and subtypes of HIV-1 in brazilian children failing HAART.
Genotypic resistance profiles in HIV-1 reverse transcriptase after 24-week therapy with nevirapine-based HAART in antiretroviral naive Thai HIV-infected children.
GENOTYPIC RESISTANCE PROFILES IN HIV-1 REVERSE TRANSCRIPTASE DURING THERAPY WITH TRIZIVIRO (ZIDOVUDINE + LAMIVUDINE + ABACAVIR) IN ANTIRETROVIRAL TREATMENT-NAIVE HIV-1-INFECTED PATIENTS.
GENOTYPIC RESISTANCE TEST IN THE DAILY CLINICAL PRACTICE TO IMPROVE THE CHOICE OF ANTIRETROVIRAL TREATMENT RESCUE: A NON-RANDOMIZED STUDY IN HIV PATIENTS WITH VIROLOGIC FAILURE IN ARGENTINA.
Genotypic resistance testing of antiretrovirals in HIV.
Genotypic Resistance to Nevirapine in HIV-1 Patients Receiving HAART.
Genotypic Resistance to Protease and Reverse Transcriptase Inhibitors and Antiretroviral History Do Not Affect Virologic Response To T-1249.
Genotypic Resistance to Protease Inhibitors (PIs) in HIV-infected Patients Who had Virologic Failure on PI-Containing Regimens Despite Good Adherence to Antiretroviral Therapy (ART): Patients Characteristics and Associated Factors.
Genotypic resistance to zidovudine (ZDV) and relationship to subsequent virological response in novavir ANRS 073 trial.